Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

26.10 -0.25 (-0.95%)
Streaming Delayed Price Updated: 10:38 AM EST, Dec 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 ↗
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy on the Dip: July 2024 ↗
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
News headline image
Expert Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
NASDAQ:PCRX: good value for what you're paying. ↗
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:PCRX, an undervalued stock with good fundamentals. ↗
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
News headline image
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That May Explode In July ↗
 
Via Benzinga
News headline image
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts ↗
 
Via Benzinga
News headline image
Navigating 4 Analyst Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
From Pacira BioSciences
Via GlobeNewswire
News headline image
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024 ↗
PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
News headline image
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.